Her3 as a determinant for the prognosis of melanoma
AssigneeMax-Planck-Gesellschaft Zur FöRderung Der Wissenschaften E. V.
InventorsAxel Ullrich, Pjotr Knyazev, Markus Reschke
Life of this patent
Estimating the term…
Abstract
Disclosed are inhibitors of HER3 for the treatment of melanoma, in particular melanoma metastases and/or refractory melanoma, pharmaceutical compositions comprising such an inhibitor and a method for the diagnosis or prognosis of melanoma.
Claims20
Inhibitor of HER3 for the treatment of melanoma metastases and/or refractory melanoma.
Pharmaceutical composition comprising an inhibitor of HER3 for the treatment of melanoma metastases and/or refractory melanoma.
13-14. (canceled)
In vitro method for the diagnosis and/or prognosis of melanoma, comprising
- (a) detecting HER3 levels in cells to be analyzed and
- (b) correlating the detected HER3 levels with proliferation, tumor progression and/or patient survival and optionally
- (c) administering an inhibitor of HER3 or a pharmaceutical composition comprising an inhibitor of HER3.
A method of treating melanoma metastases and/or refractory melanoma comprising administering an effective amount of an inhibitor of HER3.
Dependencies are inferred from the claim text.